Ipix is a pre rev biotech. The point to be a public pre rev biotech is to have the ability to finance a company through the development process which is extremely difficult. What’s the success rate? Let me know. It’s not good and very risky.
As I’ve pointed out 100 times. In 2012. There was zero human trials. They only had pre clinical K and P data.
They had zero financing.
37k in cash
92 million OS
Share price was around 70 cents
Today. 140 plus million shares. 8 successful human trials and bought B franchise. Plus3 mil in cash. Share price. .43
Reformulation is needed. Once they get first deal the cap will blow off this.
News 
Market Data 
Discover 
AI
